Effect of itraconazole and rabeprazole on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants
Efficacy with vimseltinib in patients with tenosynovial giant cell tumor and prior colony-stimulating factor 1 inhibitor therapy: a phase 2 case series
Effect of a high-fat meal on the pharmacokinetics of vimseltinib, an oral inhibitor of the colony-stimulating factor 1 receptor, in healthy participants
Impact of expert-led education programs on health care provider knowledge of gastrointestinal stromal tumor
INSIGHT: A Phase 3, Randomized, Open-Label Study of Ripretinib vs Sunitinib in Patients with Advanced Gastrointestinal Stromal Tumor Previously Treated with Imatinib with Kit Exon 11 + 17/18 Mutations
Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received No Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update.
Safety and Efficacy Updates from a Phase 1 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor
Safety, Efficacy, and Patient-Reported Outcomes with Vimseltinib in Patients with Tenosynovial Giant Cell Tumor Who Received Prior Anti-Colony-Stimulating Factor 1 Therapy: Ongoing Phase 2 Update
DCC-2618, a novel pan-KIT and PDGFRα Kinase switch control inhibitor demonstrates encouraging activity in patients (pts) with Gastrointestinal Stromal Tumors (GIST).
Phase 1 study of DCC-3014 to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with malignant solid tumors and diffuse-type tenosynovial giant cell tumor.
